Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 236

Sort by

Sort Order Select

Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Blood (2025) 146 (Supplement 1): 3889.

https://doi.org/10.1182/blood-2025-3889

Published: 2025

Journal Articles

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

Guangsheng He, Yuemin Gong, Jianyong Li, Wenwei Zhu, Jingnan Sun, Chuan He, Wei Zhang, Cuicui Han, Jie Yang, Heng Liu

Blood (2025) 146 (Supplement 1): 983.

https://doi.org/10.1182/blood-2025-983

Published: 2025

Journal Articles

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone

Yawen Zhang, Chengtao Qin, Yuemin Gong, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 2880.

https://doi.org/10.1182/blood-2025-2880

Published: 2025

Journal Articles

Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia

Chengtao Qin, Yawen Zhang, Yuemin Gong, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 6431.

https://doi.org/10.1182/blood-2025-6431

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Zhongxun Shi, Fei Huang, Yu Chen, Chun Qiao, Rong Wang, Yan Wang, Jianyong Li, Lei Fan, Wenyi Shen

Blood (2025) 146 (Supplement 1): 7362.

https://doi.org/10.1182/blood-2025-7362

Published: 2025

Journal Articles

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Blood (2025) 146 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2025-1824

Published: 2025

Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li

Blood (2025) 146 (Supplement 1): 1910.

https://doi.org/10.1182/blood-2025-1910

Published: 2025

Journal Articles

The improvement of renal function by complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria

Chengtao Qin, Yuemin Gong, Yawen Zhang, Ting Zhang, Jianyong Li, Lei Fan, Guangsheng He

Blood (2025) 146 (Supplement 1): 2892.

https://doi.org/10.1182/blood-2025-2892

Published: 2025

Journal Articles

Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study

Wenyu Shi, Huayuan Zhu, Jianyong Li, Xiaoyan Xie, Xuzhang Lu, Lei Cao, Miao Sun, Yi Xia

Blood (2025) 146 (Supplement 1): 5477.

https://doi.org/10.1182/blood-2025-5477

Published: 2025

Journal Articles

Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Ting Zhang, Xu Shen, Yuanyuan Jin, Xin Cheng, Yuan Xia, Jianyong Li, Lijuan Chen

Blood (2025) 146 (Supplement 1): 2144.

https://doi.org/10.1182/blood-2025-2144

Published: 2025

Journal Articles

Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns

Jinhua Liang, Yi-Fan Wu, Yi-Lun Ji, Liu-Qing Zhu, Li Wang, Jianyong Li, Xu Wei

Blood (2025) 146 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2025-1889

Published: 2025

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Journal Articles

A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

Jinhua Liang, Li Wang, Haorui Shen, Hua Yin, Jiazhu Wu, Yue Li, Bihui Pan, Xinyu Zhang, Yilin Kong, Jianyong Li, Xu Wei

Blood (2024) 144 (Supplement 1): 1742.3.

https://doi.org/10.1182/blood-2024-207064

Published: 2024

Journal Articles

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Blood (2024) 144 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2024-207591

Published: 2024

Journal Articles

Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Ming Hong, Bin Huang, Wenjie Liu, Qian Sun, Jianyong Li, Sixuan Qian, Qianghu Wang, Kening Li

Blood (2024) 144 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2024-198791

Published: 2024

Journal Articles

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Xiao Lu, Yeqin Sha, Xinyu Song, Luomengjia Dai, Ziyuan Zhou, Hanning Tang, Yi Miao, Shuchao Qin, Yi Xia, Tonglu Qiu, Lei Fan, Jianyong Li, Huayuan Zhu

Blood (2024) 144 (Supplement 1): 4612.

https://doi.org/10.1182/blood-2024-207729

Published: 2024

Journal Articles

Role and Mechanisms Exploration of Histamine and Its Receptors in the Progression of Peripheral T-Cell Lymphoma

Hui Jin, Ling Wang, Yimin Ren, Zijuan Wu, Wenyu Shi, Jianyong Li

Blood (2024) 144 (Supplement 1): 4378.

https://doi.org/10.1182/blood-2024-211896

Published: 2024

Journal Articles

Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Xiaoyan Qu, Yating Li, Zhengxu Sun, Wanting Ying, Hailing Liu, Sanmei Wang, Miao Zhong, Jianyong Li, Lei Fan

Blood (2024) 144 (Supplement 1): 1902.

https://doi.org/10.1182/blood-2024-206525

Published: 2024

Journal Articles

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Huayuan Zhu, Yi Miao, Shuchao Qin, Ming Liu, Yi Xia, Luomengjia Dai, Tonglu Qiu, Chong-Yang Ding, Hairong Qiu, Chun Qiao, Yujie Wu, Fei Li, Xiao Lu, Wei Xu, Lei Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2024-204881

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks

Severe hemolysis flare of refractory warm hemolytic anemia with positive complement component C3d responsive to iptacopan with cyclophosphamide and prednisone

Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

The improvement of renal function by complement inhibitors in patients with paroxysmal nocturnal hemoglobinuria

Polatuzumab vedotin combined with orelabrutinib and rituximab (PRO Regimen) as frontline therapy in elderly and frail patients with diffuse large B-cell lymphoma (DLBCL): Results from A phase II study

Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Molecular insights from ctdna dynamics: Monitoring MRD and tracking divergent progression modes and clonal evolution patterns

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with CSF3R T618I : A Multi-Centre Retrospective Study

Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Exploration of the Specific Mechanism of EGR2 Hotspot Mutation Mediating the Upregulation of Galectin-1 Expression in the Progression of CLL Following Treatment with BTK Inhibitor

Role and Mechanisms Exploration of Histamine and Its Receptors in the Progression of Peripheral T-Cell Lymphoma

Glycosylation Single-Cell Transcriptomic Profiling Decodes Driver Mechanism and Genetic Characteristics of Circulating Plasma Cells in Multiple Myeloma

Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (cwCLL-001 Study)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only